Shots:
- The P-III VANISH-303 evaluates ibrexafungerp vs PBO in patients with VVC & P-II DOVE studies assess ibrexafungerp vs fluconazole for the same indication. The results were published in America’s Clinical Infectious Diseases
- In the P-III study, the therapy was superior in completely resolving signs & symptoms of VVC @10 Day (50.5% vs 28.6%); superior mycological eradication (49.5% vs 19.4%); symptom resolution was sustained & further increased (59.6% vs 44.9%). Post hoc analysis showed similar rates of clinical cure & improvement (54.8% & 63.4%), respectively
- In the P-II DOVE study, ibrexafungerp showed similar efficacy to SC @10 Day with sustained efficacy @25 Day follow-up, was well-tolerated
Click here to read full press release/ article | Ref: Scynexis | Image: Scynexis
The post Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection first appeared on PharmaShots.
